Close Menu

NEW YORK (360Dx) — Atomo Diagnostics has signed an agreement to commercialize its CE-marked HIV self-tests in low- and middle-income nations with Mylan Pharmaceuticals, the companies announced today.

Atomo's tests use the firm's AtomoRapid technology to detect the presence of HIV antibodies from a finger prick of blood and provides results within 15 minutes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.